Diamyd Medical AB
Company Profile
Business description
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.
Contact
Kungsgatan 29
StockholmSE-111 56
SWET: +46 86610026
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
32
Stocks News & Analysis
stocks
3 global ‘buy the dip’ candidates with wide moats
stocks
What next for Nine Entertainment after Domain payout?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.70 | 18.10 | 0.20% |
| CAC 40 | 7,825.24 | 1.72 | 0.02% |
| DAX 40 | 23,698.15 | 5.50 | -0.02% |
| Dow JONES (US) | 45,834.22 | 273.78 | -0.59% |
| FTSE 100 | 9,283.29 | 14.29 | -0.15% |
| HKSE | 26,388.16 | 301.84 | 1.16% |
| NASDAQ | 22,141.10 | 98.03 | 0.44% |
| Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
| NZX 50 Index | 13,227.90 | 1.25 | -0.01% |
| S&P 500 | 6,584.29 | 3.18 | -0.05% |
| S&P/ASX 200 | 8,864.90 | 22.00 | 0.25% |
| SSE Composite Index | 3,870.60 | 4.71 | -0.12% |